Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage
Ernexa Therapeutics (Nasdaq: ERNA) appointed veteran biotech executive David Polinsky to its board, strengthening leadership as the company prepares for IND submission of its lead cell therapy ERNA-101 in Q3 2026 and plans Phase 1 clinical trial initiation in Q4 2026. Polinsky brings over 25 years of experience in oncology, capital markets, and cor…